Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden.

Brickley EB, Connor RI, Wieland-Alter WF, Collett MS, Hartford M, Van Der Avoort H, Boesch AW, Weiner JA, Ackerman ME, McKinlay MA, Arita M, Bandyopadhyay AS, Modlin JF, Wright PF.

BMJ Glob Health. 2019 Aug 28;4(4):e001613. doi: 10.1136/bmjgh-2019-001613. eCollection 2019.

2.

The Global Vaccine Action Plan - insights into its utility, application, and ways to strengthen future plans.

Daugherty MA, Hinman AR, Cochi SL, Garon JR, Rodewald LE, Nowak G, McKinlay MA, Mast EE, Orenstein WA.

Vaccine. 2019 Aug 14;37(35):4928-4936. doi: 10.1016/j.vaccine.2019.07.042. Epub 2019 Jul 17.

PMID:
31326253
3.

Global Funders Consortium for Universal Influenza Vaccine Development.

Bresee JS, McKinlay MA, Abramson J, Klugman KP, Wairagkar N; Global Funders Consortium for Universal Influenza Vaccine Development.

Vaccine. 2019 Jan 7;37(2):211-213. doi: 10.1016/j.vaccine.2018.11.037. Epub 2018 Nov 30. No abstract available.

PMID:
30503660
4.

New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.

Shaghaghi M, Soleyman-Jahi S, Abolhassani H, Yazdani R, Azizi G, Rezaei N, Barbouche MR, McKinlay MA, Aghamohammadi A.

Vaccine. 2018 Mar 20;36(13):1711-1719. doi: 10.1016/j.vaccine.2018.02.059. Epub 2018 Feb 23. Review.

PMID:
29478755
5.

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, Quinn J, Sutter RW, Wang X, Sanal O, Latysheva T, Ikinciogullari A, Bernatowska E, Tuzankina IA, Costa-Carvalho BT, Franco JL, Somech R, Karakoc-Aydiner E, Singh S, Bezrodnik L, Espinosa-Rosales FJ, Shcherbina A, Lau YL, Nonoyama S, Modell F, Modell V; JMF Centers Network Investigators and Study Collaborators, Barbouche MR, McKinlay MA.

Front Immunol. 2017 Jun 13;8:685. doi: 10.3389/fimmu.2017.00685. eCollection 2017.

6.

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells.

Mitsuuchi Y, Benetatos CA, Deng Y, Haimowitz T, Beck SC, Arnone MR, Kapoor GS, Seipel ME, Chunduru SK, McKinlay MA, Begley CG, Condon SM.

Cell Death Discov. 2017 Jan 16;3:16046. doi: 10.1038/cddiscovery.2016.46. eCollection 2017.

7.

Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.

Collett MS, Hincks JR, Benschop K, Duizer E, van der Avoort H, Rhoden E, Liu H, Oberste MS, McKinlay MA, Hartford M.

J Infect Dis. 2017 Feb 1;215(3):335-343. doi: 10.1093/infdis/jiw542.

8.

Immunization equity.

Hinman AR, McKinlay MA.

Vaccine. 2015 Nov 27;33 Suppl 4:D72-7. doi: 10.1016/j.vaccine.2015.09.033. Review.

PMID:
26615172
9.

Immunization Equity.

Hinman AR, McKinlay MA.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S399-405. doi: 10.1016/j.amepre.2015.04.018. Epub 2015 Aug 15.

PMID:
26282089
10.

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. Review.

PMID:
25316866
11.

Negative feedback regulation of NF-κB-inducing kinase is proteasome-dependent but does not require cellular inhibitors of apoptosis.

Gray CM, McCorkell KA, Chunduru SK, McKinlay MA, May MJ.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):341-6. doi: 10.1016/j.bbrc.2014.05.122. Epub 2014 Jun 2.

12.

Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies.

Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, Alexander MD, Kumar PT, Hendi MS, Lee YH, Benetatos CA, Yu G, Kapoor GS, Neiman E, Seipel ME, Burns JM, Graham MA, McKinlay MA, Li X, Wang J, Shi Y, Feltham R, Bettjeman B, Cumming MH, Vince JE, Khan N, Silke J, Day CL, Chunduru SK.

J Med Chem. 2014 May 8;57(9):3666-77. doi: 10.1021/jm500176w. Epub 2014 Apr 15.

PMID:
24684347
13.

Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.

Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee YH, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK.

Mol Cancer Ther. 2014 Apr;13(4):867-79. doi: 10.1158/1535-7163.MCT-13-0798. Epub 2014 Feb 21. Erratum in: Mol Cancer Ther. 2014 Sep;13(9):2246-7. Dosage error in article text.

14.

Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization.

Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, Chunduru SK, McKinlay MA, Vaux DL, Silke J, Day CL.

J Biol Chem. 2011 May 13;286(19):17015-28. doi: 10.1074/jbc.M111.222919. Epub 2011 Mar 10.

15.

Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.

Griffith TS, Kucaba TA, O'Donnell MA, Burns J, Benetatos C, McKinlay MA, Condon S, Chunduru S.

Apoptosis. 2011 Jan;16(1):13-26. doi: 10.1007/s10495-010-0535-3.

PMID:
20734142
16.

Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.

Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS.

Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9.

17.

Recent advances in the treatment of rhinovirus infections.

McKinlay MA.

Curr Opin Pharmacol. 2001 Oct;1(5):477-81. Review.

PMID:
11764773
18.

Pleconaril. A broad spectrum antipicornaviral agent.

Rogers JM, Diana GD, McKinlay MA.

Adv Exp Med Biol. 1999;458:69-76. Review. No abstract available.

PMID:
10549380
19.

Enterovirus meningitis in adults.

Rotbart HA, Brennan PJ, Fife KH, Romero JR, Griffin JA, McKinlay MA, Hayden FG.

Clin Infect Dis. 1998 Oct;27(4):896-8. No abstract available.

PMID:
9798053
20.

Treatment of human enterovirus infections.

Rotbart HA, O'Connell JF, McKinlay MA.

Antiviral Res. 1998 Apr;38(1):1-14. Review. No abstract available.

PMID:
9613999
21.

Human rhinovirus 14 complexed with fragments of active antiviral compounds.

Bibler-Muckelbauer JK, Kremer MJ, Rossmann MG, Diana GD, Dutko FJ, Pevear DC, McKinlay MA.

Virology. 1994 Jul;202(1):360-9.

PMID:
8009848
22.

The structure of human rhinovirus 16.

Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA, et al.

Structure. 1993 Sep 15;1(1):51-68.

PMID:
7915182
23.

Discovery and development of antipicornaviral agents.

McKinlay MA.

Scand J Infect Dis Suppl. 1993;88:109-15. Review.

PMID:
8516662
24.

Application of crystallography to the design of antiviral agents.

Rossmann MG, McKinlay MA.

Infect Agents Dis. 1992 Feb;1(1):3-10. Review.

PMID:
1365526
25.

Drugs as molecular tools.

Dutko FJ, Baright DE, Diana GD, Fox MP, Pevear DC, McKinlay MA.

Adv Exp Med Biol. 1992;312:15-24. Review. No abstract available.

PMID:
1514439
26.

Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment.

McKinlay MA, Pevear DC, Rossmann MG.

Annu Rev Microbiol. 1992;46:635-54. Review.

PMID:
1332585
27.
28.

In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA.

Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74.

29.

Crystal structure of human rhinovirus serotype 1A (HRV1A).

Kim SS, Smith TJ, Chapman MS, Rossmann MC, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA.

J Mol Biol. 1989 Nov 5;210(1):91-111.

PMID:
2555523
30.

Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound.

Heinz BA, Rueckert RR, Shepard DA, Dutko FJ, McKinlay MA, Fancher M, Rossmann MG, Badger J, Smith TJ.

J Virol. 1989 Jun;63(6):2476-85.

31.

Three-dimensional structures of drug-resistant mutants of human rhinovirus 14.

Badger J, Krishnaswamy S, Kremer MJ, Oliveira MA, Rossmann MG, Heinz BA, Rueckert RR, Dutko FJ, McKinlay MA.

J Mol Biol. 1989 May 5;207(1):163-74.

PMID:
2544734
32.

Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril.

Jubelt B, Wilson AK, Ropka SL, Guidinger PL, McKinlay MA.

J Infect Dis. 1989 May;159(5):866-71.

PMID:
2540248
33.

Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors.

Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ.

J Virol. 1989 May;63(5):2002-7.

34.

Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus.

Diana GD, Cutcliffe D, Oglesby RC, Otto MJ, Mallamo JP, Akullian V, McKinlay MA.

J Med Chem. 1989 Feb;32(2):450-5.

PMID:
2913305
35.

Inhibitors of viral uncoating.

Diana GD, Pevear DC, Otto MJ, McKinlay MA, Rossmann MG, Smith T, Badger J.

Pharmacol Ther. 1989;42(3):289-305. Review. No abstract available.

PMID:
2672048
36.

Rational design of antiviral agents.

McKinlay MA, Rossmann MG.

Annu Rev Pharmacol Toxicol. 1989;29:111-22. Review.

PMID:
2658767
37.

Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14.

Diana GD, Otto MJ, Treasurywala AM, McKinlay MA, Oglesby RC, Maliski EG, Rossmann MG, Smith TJ.

J Med Chem. 1988 Mar;31(3):540-4.

PMID:
2831362
38.

Inhibition of poliovirus uncoating by disoxaril (WIN 51711).

Zeichhardt H, Otto MJ, McKinlay MA, Willingmann P, Habermehl KO.

Virology. 1987 Sep;160(1):281-5.

PMID:
2820136
39.

Recent developments in antiviral chemotherapy.

McKinlay MA, Otto MJ.

Infect Dis Clin North Am. 1987 Jun;1(2):479-93. Review.

PMID:
3332799
40.

Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating.

Diana GD, Oglesby RC, Akullian V, Carabateas PM, Cutcliffe D, Mallamo JP, Otto MJ, McKinlay MA, Maliski EG, Michalec SJ.

J Med Chem. 1987 Feb;30(2):383-8.

PMID:
3027340
41.

Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice.

McKinlay MA, Frank JA Jr, Benziger DP, Steinberg BA.

J Infect Dis. 1986 Oct;154(4):676-81.

PMID:
3745975
42.

The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating.

Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana GD, Otto MJ.

Science. 1986 Sep 19;233(4770):1286-93.

PMID:
3018924
43.

Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug.

Fox MP, Otto MJ, McKinlay MA.

Antimicrob Agents Chemother. 1986 Jul;30(1):110-6.

44.

Oral efficacy of WIN 51711 in mice infected with human poliovirus.

McKinlay MA, Steinberg BA.

Antimicrob Agents Chemother. 1986 Jan;29(1):30-2.

45.

[[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating.

Diana GD, McKinlay MA, Otto MJ, Akullian V, Oglesby C.

J Med Chem. 1985 Dec;28(12):1906-10.

PMID:
2999407
46.

WIN 51711, a new systematically active broad-spectrum antipicornavirus agent.

McKinlay MA.

J Antimicrob Chemother. 1985 Sep;16(3):284-6. No abstract available.

PMID:
4055541
47.

In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.

Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA.

Antimicrob Agents Chemother. 1985 Jun;27(6):883-6.

48.

Isoxazoles with antipicornavirus activity.

Diana GD, McKinlay MA, Brisson CJ, Zalay ES, Miralles JV, Salvador UJ.

J Med Chem. 1985 Jun;28(6):748-52.

PMID:
2989517
49.

Inhibitors of picornavirus uncoating as antiviral agents.

Diana GD, Otto MJ, McKinlay MA.

Pharmacol Ther. 1985;29(3):287-97. Review. No abstract available.

PMID:
3014575
50.

Virucidal activity of glutaric acid and evidence for dual mechanism of action.

Kuhrt MF, Fancher MJ, McKinlay MA, Lennert SD.

Antimicrob Agents Chemother. 1984 Dec;26(6):924-7.

Supplemental Content

Loading ...
Support Center